The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy.
about
Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapyCost of treatment in a US commercially insured, HIV-1-infected populationSuper Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring.Timing of pregnancy, postpartum risk of virologic failure and loss to follow-up among HIV-positive women.Adherence to antiretroviral therapy and HIV transmission risks: implications for test-and-treat approaches to HIV prevention.Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.Resistance evolution in HIV - modeling when to intervene.Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level.Stress and poverty predictors of treatment adherence among people with low-literacy living with HIV/AIDS.Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring.Benefits of adherence to psychotropic medications on depressive symptoms and antiretroviral medication adherence among men and women living with HIV/AIDS.Virological breakthrough: a risk factor for loss to followup in a large community-based cohort on antiretroviral therapy.Clinical management of HIV drug resistance.Effect of mobile telephone reminders on treatment outcome in HIV: evidence from a randomised controlled trial in IndiaDefining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigmAdherence and Risk Behaviour in Patients with HIV Infection Receiving Antiretroviral Therapy in Bangkok.Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA.Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa.Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-AnalysisRe-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV.Motivational Enhancement System for Adherence (MESA): pilot randomized trial of a brief computer-delivered prevention intervention for youth initiating antiretroviral treatment.Relationship between viral load and behavioral measures of adherence to antiretroviral therapy in children living with human immunodeficiency virus in Latin AmericaA Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort StudyComparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.Cost-effectiveness of raltegravir in HIV/AIDS.A meta-analysis of adherence to antiretroviral therapy and virologic responses in HIV-infected children, adolescents, and young adults.Role of raltegravir in HIV-1 management.Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why?Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda.Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression.Determinants of virological failure and antiretroviral drug resistance in Mozambique.Food insufficiency and medication adherence among people living with HIV/AIDS in urban and peri-urban settings.Correlation of Adherence by Pill Count, Self-report, MEMS and Plasma Drug Levels to Treatment Response Among Women Receiving ARV Therapy for PMTCT in Kenya.Factors associated with therapeutic success in HIV-positive individuals in southern Brazil.Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score.An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy.Plasma HIV-1 RNA levels during antiretroviral therapy: how low is low enough?
P2860
Q28478666-B217EA8C-7B32-438D-B4CE-5A6B5A9A7F55Q28539139-C11FAC3B-821C-4B45-9B62-DEFA584A3B98Q30944694-8749AF8A-4C0B-44F9-91A9-EB072A08C1EBQ33853679-F172C63C-C34F-48B5-AA6F-975B37A3B9A5Q33874948-BD393B53-A8F4-456D-8EA6-285F9BFC8636Q33952538-46C66FD1-3494-4204-8E4C-6453AED3D527Q34247013-CB3B8008-0AAB-466D-920C-A977160509A9Q34283336-4D605BCF-F2B3-4F81-B017-F5D30B79F734Q34468878-0B7D2BFB-020D-42BD-8A19-7D7558450EEAQ34699180-7D1DA902-5D19-40EE-AF0B-409F7BF1A596Q34845860-226087EB-878E-48CD-BC96-D2F730B24AD7Q35058006-C5BAE46C-F586-40C0-AFE3-12C09C041C4AQ35261045-B9AE6B8E-E585-4B0D-AE62-2B2C9E923158Q35693038-736B81E4-3E0B-4A8A-9B1D-9063A6874552Q35780443-DB20E8E2-B944-48B2-8886-753BFB1EF96AQ35810259-4DDE1B3A-316C-4E2C-9B1F-E60D5FEBB496Q36113560-84F8510D-34AD-4721-9CC2-322ACD54D99DQ36219891-325E144E-8D30-4F37-9EC0-556C73E8B091Q36224801-2C54C5B0-4A61-4ACE-863B-9B5A6EB7BDA0Q36822464-0D756A13-3462-4976-96DA-CF7F6A8EE2EEQ36892497-F5B8D3C6-99D8-44FB-BD79-ABC03F6E4F95Q36981553-76C39917-A01B-47CB-BADC-C71BB6B19BF9Q37015463-B7884E49-6496-4544-9BE6-1B829089DDC2Q37091685-CB82E144-26E7-459A-A33F-5A2AAD5847D7Q37782179-CFA07ED9-D814-4248-A713-ED48082AC68AQ37958046-A14740AD-D516-4F01-B517-674ACAA9826DQ37992958-21D5DD1F-3389-40CC-8E8D-5EF4AD4368F1Q38002011-3BCFEBD2-9666-4E8A-8BE3-B9D5F2ABB7BCQ38818789-06E76C27-F5D6-4C76-8EDB-C940A3C665A8Q38854329-D861861B-34C3-4335-A5B1-B96A5B502B0EQ38860584-DC4B2F99-BF5A-4CF3-B68E-EE09495A87D9Q39359637-4F60209D-23DF-4962-8AFF-018AD7F66F54Q39414398-C7C1B308-48D2-4EE5-8A62-61C0D769E072Q39984282-C031B31C-6E01-44FB-8F5E-44D8A50C5B81Q40335852-3AD978C0-D3AD-42C0-9781-79DF16F0A633Q41649688-1F9E84E2-5B1F-48BA-92C4-7025F434AF5EQ42213902-0C9827C5-6575-4B3B-AE44-C02E3C024FDDQ42260250-169EDAE8-D9D6-4718-AD58-CADF790B06B3Q42263784-6E9017DE-8639-4411-AD61-31DE48D0222BQ42630054-BA488B44-9F49-49CA-BAA6-41E8C479FBD0
P2860
The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The risk of virologic failure ...... nce to antiretroviral therapy.
@ast
The risk of virologic failure ...... nce to antiretroviral therapy.
@en
type
label
The risk of virologic failure ...... nce to antiretroviral therapy.
@ast
The risk of virologic failure ...... nce to antiretroviral therapy.
@en
prefLabel
The risk of virologic failure ...... nce to antiretroviral therapy.
@ast
The risk of virologic failure ...... nce to antiretroviral therapy.
@en
P2860
P1433
P1476
The risk of virologic failure ...... nce to antiretroviral therapy.
@en
P2093
Mark van der Laan
Michael Rosenblum
P2860
P356
10.1371/JOURNAL.PONE.0007196
P407
P577
2009-09-29T00:00:00Z